Raymond James & Associates’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Raymond James & Associates’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,468	Closed	-$281K	–	4289
2022 Q1	$281K	Buy	10,468 +1,598	+18%	+$53.7K	﹤0.01%	3459
2021 Q4	$423K	Sell	8,870 -1,128	-11%	-$50.4K	﹤0.01%	3210
2021 Q3	$664K	Sell	9,998 -363	-4%	-$25.9K	﹤0.01%	2859
2021 Q2	$808K	Sell	10,361 -90	-0.9%	-$6.65K	﹤0.01%	2733
2021 Q1	$989K	Sell	10,451 -131	-1%	-$15.6K	﹤0.01%	2522
2020 Q4	$1.29M	Sell	10,582 -484	-4%	-$53K	﹤0.01%	2169
2020 Q3	$967K	Sell	11,066 -266	-2%	-$18.5K	﹤0.01%	2200
2020 Q2	$732K	Buy	+11,332	New	+$654K	﹤0.01%	2352

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Raymond James & Associates's TPTX Position: Q2 2022 in Review

Raymond James & Associates sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 10,468 shares — an estimated $281K sold.

Raymond James & Associates first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $1.29M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Raymond James & Associates reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Raymond James & Associates sold 10,468 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $281K.
Raymond James & Associates first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Raymond James & Associates's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.29M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.